Jacobs and Tula Sign Cooperation Agreement to Further Support Customers Adopting CDA With Dynamic Skip Fire Technology
Jacobs Vehicle Systems and Tula Technology have signed a cooperation agreement to accelerate the development of Jacobs Cylinder Deactivation® (CDA®) valve actuation technology in conjunction with Tula’s Dynamic Skip Fire (DSF®) control algorithms. The agreement builds on two years of research and development collaboration between the two companies to reduce nitrous oxide (NOX) and carbon dioxide (CO2) emissions from medium and heavy-duty vehicles, helping to meet ever-tightening environmental regulations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005336/en/
Jacobs Vehicle Systems and Tula Technology are exploring opportunities to reduce NOx and CO₂ emissions and will equip Jacobs’ newest demonstrator truck with both Jacobs’ CDA and Tula’s diesel DSF technologies for customers to experience firsthand. (Photo: Business Wire)
“Jacobs Vehicle Systems and Tula Technology are both great companies with great technologies, and we’ve been even more effective working together,” said John Fuerst, senior vice president of technology and innovation at Tula. “This agreement will advance our capabilities to produce better CDA products and dDSF controls.”
Independent laboratory testing has demonstrated that Jacobs CDA hardware and Tula’s dDSF achieve greater emission reductions when combined. Low-load cycle performance was estimated with a well-calibrated powertrain simulation tool to accurately capture the low-load system operation and emissions. This system showed as much as a 5% decrease in CO2 and a 74% reduction in NOX emissions compared to the baseline technology.
“While CDA and dDSF are available to commercial powertrain manufacturers as separate systems, our experience indicates that integrating the two technologies delivers much greater benefit to today’s medium- and heavy-duty engines,” said Steve Ernest, vice president of engineering and business development at Jacobs Vehicle Systems. “We have been working with Tula for several years, and this formal agreement solidifies our relationship as we demonstrate the benefits of using CDA and dDSF in tandem. Our efforts will provide the marketplace with sought-after solutions to meet increasingly challenging emissions standards. The synergies created through multiple development projects will offer customers the best possible outcomes for reducing NOX and CO2 simultaneously.”
The agreement will allow technical development to expand the operating range at which emissions reductions can be achieved when the two technologies are combined. Jacobs and Tula also will explore opportunities for reduced NOX and CO2 emissions in off-road vehicles and equip a Class 8 demonstrator truck with both Jacobs’ CDA and Tula’s diesel DSF technologies for customers to experience firsthand.
About Jacobs Vehicle Systems
Jacobs Vehicle Systems is headquartered in Bloomfield, Conn., where it has a 25,000 square meter design, testing, and manufacturing facility, with support sites in Europe, Japan, and India as well as manufacturing facilities in Suzhou, China, and Brno, Czech Republic. Jake Brake® products are used by heavy and medium-duty diesel engine manufacturers globally. Registered to the ISO 14001 and IATF16949 standards, Jacobs Vehicle Systems is a leading producer of vehicle retarding and valve actuation technologies and can be found at jakebrake.com.
About Tula Technology, Inc.
Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 378 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005336/en/
Contact information
Jacobs Vehicle Systems
Mike O’Neill
Mike@oneillpublicrelations.com
215-485-1282
Tula Technology, Inc.
Ram Subramanian
Principal Marketing Strategist
ram@tulatech.com
Media:
Financial Profiles
Debbie Douglas, SVP
ddouglas@finprofiles.com
949-375-3436
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release
Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release
Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 18:00:00 EEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom